Full name
CENTRUM BADAWCZO ROZWOJOWE INOVA SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
72.11.Z - Research and experimental development on biotechnology
32.50.Z - Manufacture of medical and dental instruments and supplies
46.46.Z - Wholesale of pharmaceutical goods
58.29.Z - Other software publishing
61.90.Z - Other telecommunications activities
62.01.Z - Computer programming activities
62.02.Z - Computer consultancy activities
63.11.Z - Data processing, hosting and related activities
70.22.Z - Business and other management consultancy activities
72.19.Z - Other research and experimental development on natural sciences and engineering
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 0,9 | -0,1 | -0,1 | 0 |
EBITDA | 0,9 | -0,1 | -0,1 | 0 |
Short time liabilities | 47,3 | 48,5 | 48,5 | 0 |
Equity capital | -35,5 | -35,6 | -35,7 | -0,3 |
Operating profit (EBIT) | 0,9 | -0,1 | -0,1 | 0 |
Assets | 11,8 | 13 | 12,8 | -0,9 |
Net profit (loss) | 0,9 | -0,1 | -0,1 | 0 |
Cash | 10,6 | 10,5 | 10,4 | -1,1 |
Net income from sale | 1 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 47,3 | 48,5 | 48,5 | 0 |
Working assets | 11,8 | 13 | 12,8 | -0,9 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -2,6 | 0,3 | 0,3 | 0 |
Equity capital to total assets | -299,3 | -274,6 | -278,1 | -3,5 |
Gross profit margin | 93 | 15,9 | ||
EBITDA Margin | 93 | 15,9 | ||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 17 270 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 0.25042882561683655 | 0.26694902777671814 | 0.26447707414627075 | 0 |
Net dept to EBITDA | -11.410562515258789 | -245.92999267578125 | -246.92999267578125 | -1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane